Medical Proteoscope Co., Ltd.

Medical Proteoscope Co., Ltd. (MPS) is a Japanese company based in Yokohama that specializes in proteomics technology development and contract analysis services. According to its official website, the company positions itself as an expert in proteomics, developing analytical technologies and applying them to medicine and biology, while also offering established analytical methods as contract services to research institutions to help raise the level of omics research in Japan. Its core technical platform is label-free LC-MS/MS, which it describes as offering exceptional reliability, supported by in-house software development including i-OPAL and i-RUBY, and by quality control systems for measurement data and sample/data management. MPS operates primarily as a research and development company and a contract research organization (CRO) for proteome analysis and protein analysis. Its service menu includes label-free proteomics, phosphoproteome analysis, exosome analysis, pull-down sample analysis, plasma/serum proteome analysis, quantitative analysis of individual proteins, multi-sample proteome analysis, proteome data analysis support, identification of glycan binding sites, "proteome depth 6000" analysis, and protein band identification using SDS-PAGE and gel staining. It also offers research support and full-support packages for proteome analysis. The company states that it is one of the few domestic Japanese R&D companies dedicated to proteome analysis and protein analysis. It aims to contribute to medicine and biology through these technologies and to support the development of the protein research community. Its business spans biomarker discovery for personalized medicine, drug discovery and diagnostic development, and contract analysis for research institutions. The company also reports collaborative research and publications, including identification of target proteins of kinase inhibitors, biomarkers related to perineural invasion in pancreatic cancer, identification of Talin-1 as a marker of multistep progression in liver cancer, predictive markers for postoperative chemotherapy prognosis (myosin IIa and vimentin), and plasma protein groups correlating with the efficacy of Kampo medicines. It registers data to jPOST, a Japanese proteome data repository. MPS was founded with the aspiration that advances in cutting-edge science centered on proteome analysis would contribute to a richer society. It began its contract analysis business focused on blood proteome analysis with the aim of biomarker development, and has since accumulated achievements in analysis using formalin-fixed paraffin-embedded (FFPE) tissue samples. The company has received public recognition, including selection for a Yokohama City trial subsidy, and continues to announce new services and seminars. Its activities reflect the growing importance of biomarkers in drug development and regulation, a trend it links to the U.S. FDA's 2004 "Innovation or Stagnation" white paper and the subsequent Critical Path Initiative, as well as collaboration between the FDA and the European Medicines Agency (EMEA).

Medical Proteoscope Co., Ltd. (MPS) is a Japanese company headquartered in Yokohama that specializes in proteomics technology development and contract analysis. The company was established with the aspiration that the results of cutting-edge science centered on proteome analysis would contribute to the creation of a prosperous society. According to its official website, MPS began its contract analysis business focused on blood proteome analysis with the aim of biomarker development, and has since expanded its achievements to include analysis using formalin-fixed paraffin-embedded (FFPE) tissue samples. The company's business is built around proteome analysis, which it describes as an essential technology for drug discovery and biomarker development, as well as for the quantitative measurement and quality control of protein products including biopharmaceuticals. MPS states that it is one of the few domestic Japanese research and development companies dedicated to proteome analysis and protein analysis. It uses these technologies to contribute to medicine and biology and to support the development of the protein research community. MPS's technical platform centers on label-free LC-MS/MS, which it presents as offering exceptional reliability, supported by in-house software development including i-OPAL and i-RUBY, and by systems for quality control of measurement data and for sample and data management. The company also emphasizes collaboration among contract analysis companies. In its company message, MPS places its work in the context of international trends in biomarker development. It notes that biomarker development and application in pharmaceutical development gained greater emphasis after the U.S. Food and Drug Administration (FDA) published its 2004 medical product development white paper "Innovation or Stagnation," and that in 2006 a national project, the Critical Path Initiative, began, with biomarker development listed as a concrete theme. It also notes that the European Medicines Agency (EMEA) established a joint development framework with the FDA, and that in Europe and the United States biomarkers are expected to become increasingly important and even mandatory in new drug development, review, and approval. MPS has accumulated expertise through commissioned tests and joint research, including clinical research management technology (handling of clinical samples and systems to ensure test quality and reliability), sample pretreatment and measurement technology (pretreatment of blood and other body fluids, cells, and tissues, and LC-MS/MS measurement), and bioinformatics. The company reports research results including identification of target proteins of kinase inhibitors, biomarkers related to perineural invasion in pancreatic cancer, identification of Talin-1 as a marker molecule in multistep progression of liver cancer, predictive markers for postoperative chemotherapy prognosis (myosin IIa and vimentin), and identification of plasma protein groups that show a quantitative correlation with the efficacy of Kampo medicines. It registers data to jPOST, a Japanese proteome data repository. In recent years, MPS has continued to announce new services and activities. In June 2025 it launched a new plasma/serum proteome analysis service, and at the end of that month it announced that it had been selected for a Yokohama City trial subsidy. In August 2025 it announced the first round of its 2025 proteome analysis contract campaign and launched a "Data analysis support & measurement only plan." The company also holds proteome analysis seminars and updates its service pages, with announcements continuing into 2026.

• Contract analysis results published in a paper

• Launched new plasma/serum proteome analysis service

• Announced selection for Yokohama City trial subsidy

• Announced 2025 proteome analysis contract campaign first round and launched 'Data analysis support & measurement only plan'

• Announced proteome analysis seminar

• Announced second proteome analysis seminar of 2026

• Updated quantitative proteome analysis page

• Research supported by the company published in a paper

• Updated quantitative analysis page

A domestic Japanese R&D company and contract analysis provider specializing in proteome analysis and protein analysis, aiming to contribute to personalized medicine, drug discovery, and diagnostic development.

• Label-free LC-MS/MS proteomics platform

  Core analytical platform described as offering exceptional reliability and technical development.

• i-OPAL

  In-house developed software for proteome analysis.

• i-RUBY

  In-house developed software for proteome analysis.

• Phosphoproteome analysis

  Contract analysis service for phosphorylated proteins.

• Exosome analysis

  Contract analysis service for exosomes.

• Plasma/serum proteome analysis

  Contract analysis service for plasma and serum samples; new service launched in June 2025.

• Proteome depth 6000

  Deep proteome analysis service.

• Protein band identification (SDS-PAGE and gel staining)

  Service for identifying proteins in gel bands.

1. 1Medical Proteoscope official websitemedicalproteoscope.com
2. 2Company overviewmedicalproteoscope.com
3. 3Wikidata entry for Medical Proteoscope Co., Ltd. (Japan)wikidata.org